Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term lurasidone study in adolescents with schizophrenia
jRCT2011210024Phase 3Completed
- Sponsor
- Sumitomo Pharma
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lurasidone in schizophrenia, sponsored by Sumitomo Pharma. Primary endpoint: Safety and tolerability. Started Jul 2021; status: completed.
02
Drugs
lurasidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2011210024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210024.